Hregen

H-regen is a South Korean biotechnology company focused on developing regenerative therapies for sensorineural hearing loss. The company utilizes a proprietary platform to stimulate the regeneration of auditory hair cells by targeting LGR5-positive progenitor cells within the cochlea. Their lead program, HRG-001, is a small molecule therapeutic designed to restore hearing function by inducing the differentiation of supporting cells into new, functional hair cells. Founded by experts from Seoul National University, H-regen is positioning itself as a leader in the otology space, addressing conditions that currently lack effective pharmacological treatments. The company's approach leverages advanced understanding of inner ear biology to provide a potential cure for permanent hearing impairment.